Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Subscribe to Free Drug Patent Expiration Updates

Also available in a Drug Patent Expiration NewsletterRSS feed and on Drug Patent Expirations on TwitterTwitter

DrugPatentWatch Archives

You are currently viewing the 2000 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ERYTHROCIN STEARATE

« Back to Dashboard
Erythrocin Stearate is a drug marketed by Arbor Pharms Llc and is included in one NDA.

The generic ingredient in ERYTHROCIN STEARATE is erythromycin stearate. There are ninety-five drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.

Summary for Tradename: ERYTHROCIN STEARATE


Clinical Trials for: ERYTHROCIN STEARATE

Erythromycin Versus Azithromycin in Preterm Premature Rupture of Membranes
Status: Withdrawn Condition: Preterm Premature Ruptured Membranes

Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis
Status: Recruiting Condition: FAP-Familial Adenomatous Polyposis

Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version
Status: Not yet recruiting Condition: FAP-Familial Adenomatous Polyposis

Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis
Status: Terminated Condition: Gastroparesis

Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
Status: Recruiting Condition: Epidermolysis Bullosa

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)
Status: Completed Condition: Hepatitis C Virus

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
Status: Completed Condition: Healthy; Renal Insufficiency

Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding
Status: Recruiting Condition: Gastrointestinal Hemorrhage; Hematemesis

Intravenous Erythromycin Before Endoscopy in Patients With Variceal Bleeding: A Randomized, Double-Blind Trial
Status: Completed Condition: Variceal Bleeding

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis
Status: Completed Condition: Blepharitis

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
erythromycin stearate
Tablet; Oral060359-001Approved prior to Jan 1, 1982RXNo<disabled><disabled>
erythromycin stearate
Tablet; Oral060359-003Approved prior to Jan 1, 1982RXYes<disabled><disabled>
erythromycin stearate
Tablet; Oral060359-002Approved prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn